Controlled release of imatinib mesylate from PLGA microspheres inhibit craniopharyngioma mediated angiogenesis

Journal of Materials Science: Materials in Medicine

Volumn 24, Issue 1, 2013, Pages 147-153

  Karal Yilmaz, Oksan ^a   Ozkan, Abdulkadir ^b   Akgun, Emel ^f   Kukut, Manolya ^a   Baysal, Kemal ^a,c   Avsar, Timucin ^b,e   Kilic, Turker ^d  

^a MATERIALS INSTITUTE   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

^c DOKUZ EYLUL UNIVERSITY   (Turkey)

^d BAHCESEHIR UNIVERSITY   (Turkey)

^e ISTANBUL TECHNICAL UNIVERSITY   (Turkey)

^f KOCAELI UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACID RATIO; ANGIOGENESIS; CONTROLLED RELEASE; CRANIOPHARYNGIOMAS; ENCAPSULATION EFFICIENCY; IMATINIB; IMATINIB MESYLATE; IN-VITRO; IN-VIVO; LOCAL DELIVERY; NEOVASCULARIZATION; PLGA MICROSPHERES; POLY LACTIC-CO-GLYCOLIC ACID; RECURRENT TUMORS; THERAPEUTIC STRATEGY; TUMOR SAMPLES;

COPOLYMERS; ENCAPSULATION; SCANNING ELECTRON MICROSCOPY; TUMORS;

MICROSPHERES;

IMATINIB; MICROSPHERE; POLYGLACTIN;

ARTICLE; CANCER INHIBITION; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CRANIOPHARYNGIOMA; ENCAPSULATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY;

ANTINEOPLASTIC AGENTS; BENZAMIDES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRANIOPHARYNGIOMA; LACTIC ACID; MICROSPHERES; NEOVASCULARIZATION, PATHOLOGIC; PIPERAZINES; POLYGLYCOLIC ACID; PYRIMIDINES; SPECTROPHOTOMETRY, ULTRAVIOLET;

RATTUS;

EID: 84872405222     PISSN: 09574530     EISSN: 15734838     Source Type: Journal    
DOI: 10.1007/s10856-012-4784-2     Document Type: Article

References (41)

1. Garnett MR, Puget S, Grill J, Sainte-Rose C. Craniopharyngioma. Orphanet J Rare Dis. 2007;2:18. doi: 10.1186/1750-1172-2-18.
2. Karavitaki N, Brufani C, Warner JT, Adams CB, Richards P, Ansorge O, et al. Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up. Clin Endocrinol (Oxf). 2005;62(4):397-409. doi: 10.1111/j.1365-2265.2005.02231.x.
3. Symon L, Pell MF, Habib AH. Radical excision of craniopharyngioma by the temporal route: a review of 50 patients. Br J Neurosurg. 1991;5(6):539-49.
4. Yasargil MG, Curcic M, Kis M, Siegenthaler G, Teddy PJ, Roth P. Total removal of craniopharyngiomas. Approaches and long-term results in 144 patients. J Neurosurg. 1990;73(1):3-11.
5. Habrand JL, Ganry O, Couanet D, Rouxel V, Levy-Piedbois C, Pierre-Kahn A, et al. The role of radiation therapy in the management of craniopharyngioma: a 25-year experience and review of the literature. Int J Radiat Oncol Biol Phys. 1999;44(2):255-63.
6. Folkman J. Angiogenesis. Annu Rev Med. 2006;57:1-18.
7. Vidal S, Kovacs K, Lloyd RV, Meyer FB, Scheithauer BW. Angiogenesis in patients with craniopharyngiomas: correlation with treatment and outcome. Cancer. 2002;94(3):738-45. doi: 10.1002/cncr.10281.
8. Xu J, You C, Zhang S, Huang S, Cai B, Wu Z, et al. Angiogenesis and cell proliferation in human craniopharyngioma xenografts in nude mice. J Neurosurg. 2006;105(4 Suppl):306-10.
9. Xu J, Zhang S, You C, Wang X, Zhou Q. Microvascular density and vascular endothelial growth factor have little correlation with prognosis of craniopharyngioma. Surg Neurol. 2006;66(Suppl 1):S30-4. doi: 10.1016/j.surneu.2006.05.047.
10. Sun HI, Akgun E, Bicer A, Ozkan A, Bozkurt SU, Kurtkaya O, et al. Expression of angiogenic factors in craniopharyngiomas: implications for tumor recurrence. Neurosurgery. 2010;66(4):744-50.
11. Kilic T, Alberta JA, Zdunek PR, Acar M, Iannarelli P, O'Reilly T, et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 2000;60(18):5143-50.
12. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358(19):2039-49.
13. Mu L, Feng SS. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J Control Release. 2003;86(1):33-48.
14. Okada H, Toguchi H. Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carrier Syst. 1995;12(1):1-99.
15. Lam XM, Duenas ET, Daugherty AL, Levin N, Cleland JL. Sustained release of recombinant human insulin-like growth factor-I for treatment of diabetes. J Control Release. 2000;67(2-3):281-92.
16. Cohen S, Yoshioka T, Lucarelli M, Hwang LH, Langer R. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm Res. 1991;8(6):713-20.
17. Whittlesey KJ, Shea LD. Delivery systems for small molecule drugs, proteins, and DNA: the neuroscience/biomaterial interface. Exp Neurol. 2004;190(1):1-16. doi: 10.1016/j.expneurol.2004.06.020.
18. Lagarce F, Faisant N, Desfontis JC, Marescaux L, Gautier F, Richard J, et al. Baclofen-loaded microspheres in gel suspensions for intrathecal drug delivery: in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2005;61(3):171-80. doi: 10.1016/j.ejpb.2005.04.004.
19. Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997;28(1):5-24.
20. Benny O, Duvshani-Eshet M, Cargioli T, Bello L, Bikfalvi A, Carroll RS, et al. Continuous delivery of endogenous inhibitors from poly(lactic-co-glycolic acid) polymeric microspheres inhibits glioma tumor growth. Clin Cancer Res. 2005;11(2 Pt 1):768-76.
21. Yemisci M, Bozdag S, Cetin M, Soylemezoglu F, Capan Y, Dalkara T, et al. Treatment of malignant gliomas with mitoxantrone-loaded poly (lactide-co-glycolide) microspheres. Neurosurgery. 2006;59(6):1296-302. doi: 10.1227/01.NEU.0000245607.99946.8F. discussion 302-3.
22. Benny O, Menon LG, Ariel G, Goren E, Kim SK, Stewman C, et al. Local delivery of poly lactic-co-glycolic acid microspheres containing imatinib mesylate inhibits intracranial xenograft glioma growth. Clin Cancer Res. 2009;15(4):1222-31. doi: 10.1158/1078-0432.CCR-08-1316.
23. Ong BY, Ranganath SH, Lee LY, Lu F, Lee HS, Sahinidis NV, et al. Paclitaxel delivery from PLGA foams for controlled release in post-surgical chemotherapy against glioblastoma multiforme. Biomaterials. 2009;30(18):3189-96. doi: 10.1016/j.biomaterials.2009.02.030.
24. Ranganath SH, Fu Y, Arifin DY, Kee I, Zheng L, Lee H-S, et al. The use of submicron/nanoscale PLGA implants to deliver paclitaxel with enhanced pharmacokinetics and therapeutic efficacy in intracranial glioblastoma in mice. Biomaterials. 2010;31(19):5199-207. doi: 10.1016/j.biomaterials.2010.03.002.
25. O'Donnell PB, McGinity JW. Preparation of microspheres by the solvent evaporation technique. Adv Drug Deliv Rev. 1997;28(1):25-42. doi: 10.1016/s0169-409x(97)00049-5.
26. Auerbach R, Akhtar N, Lewis RL, Shinners BL. Angiogenesis assays: problems and pitfalls. Cancer Metastasis Rev. 2000;19(1-2):167-72.
27. Toktas ZO, Akgun E, Ozkan A, Bozkurt SU, Bekiroglu N, Seker A, et al. Relationship of angiogenic potential with clinical features in cranial meningiomas: a corneal angiogenesis study. Neurosurgery. 2010;67(6):1724-32. doi: 10.1227/NEU.0b013e3181f9f310. discussion 32.
28. Konya D, Yildirim O, Kurtkaya O, Kilic K, Black PM, Pamir MN, et al. Testing the angiogenic potential of cerebrovascular malformations by use of a rat cornea model: usefulness and novel assessment of changes over time. Neurosurgery. 2005;56(6):1339-45. discussion 45-6.
29. Kilic K, Konya D, Kurtkaya O, Sav A, Pamir MN, Kilic T. Inhibition of angiogenesis induced by cerebral arteriovenous malformations using gamma knife irradiation. J Neurosurg. 2007;106(3):463-9. doi: 10.3171/jns.2007.106.3.463.
30. Ozkan A, Guduk M, Atabay KD, Uyar SB, Seker A, Konya D, et al. High angiogenic potential in an in vivo rat corneal model is associated with shorter disease-free survival in low-grade oligodendrogliomas. J Clin Neurosci. 2010;18(1):109-13. doi: 10.1016/j.jocn.2010.05.034.
31. Auerbach R, Lewis R, Shinners B, Kubai L, Akhtar N. Angiogenesis assays: a critical overview. Clin Chem. 2003;49(1):32-40.
32. Jain RK, Schlenger K, Hockel M, Yuan F. Quantitative angiogenesis assays: progress and problems. Nat Med. 1997;3(11):1203-8.
33. Fahlbusch R, Honegger J, Paulus W, Huk W, Buchfelder M. Surgical treatment of craniopharyngiomas: experience with 168 patients. J Neurosurg. 1999;90(2):237-50.
34. Karavitaki N, Cudlip S, Adams CB, Wass JA. Craniopharyngiomas. Endocr Rev. 2006;27(4):371-97. doi: 10.1210/er.2006-0002.
35. Vidal S, Scheithauer BW, Kovacs K, Lloyd RV. Angiogenesis and the growth potential of craniopharyngiomas. Endocr Pathol. 2005;16(3):219-28. EP:16:3:219 [pii].
36. Fakhrai N, Neophytou P, Dieckmann K, Nemeth A, Prayer D, Hainfellner J, et al. Recurrent spinal ependymoma showing partial remission under Imatimib. Acta Neurochir. 2004;146(11):1255-8. doi: 10.1007/s00701-004-0374-5.
37. Bihorel S, Camenisch G, Gross G, Lemaire M, Scherrmann J-M. Influence of hydroxyurea on imatinib mesylate (gleevec) transport at the mouse blood-brain barrier. Drug Metab Dispos. 2006;34(12):1945-9. doi: 10.1124/dmd.106.010975.
38. Wen PY, Yung WKA, Lamborn KR, Dahia PL, Wang Y, Peng B, et al. Phase I/II study of Imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res. 2006;12(16):4899-907. doi: 10.1158/1078-0432.ccr-06-0773.
39. Fredenberg S, Wahlgren M, Reslow M, Axelsson A. The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems - a review. Int J Pharm. 2011;415(1-2):34-52. doi: 10.1016/j.ijpharm.2011.05.049.
40. Lee Y-H, Mei F, Bai M-Y, Zhao S, Chen D-R. Release profile characteristics of biodegradable-polymer-coated drug particles fabricated by dual-capillary electrospray. J Controlled Release. 2010;145(1):58-65. doi: 10.1016/j.jconrel.2010.03.014.
41. Berkland C, Kim K, Pack DW. PLG microsphere size controls drug release rate through several competing factors. Pharm Res. 2003;20(7):1055-62.